La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Editas Medicine Gestion

Gestion contrôle des critères 2/4

Le PDG Editas Medicine's est Gilmore O’Neill, nommé en Jun2022, a un mandat de 2.17 ans. La rémunération annuelle totale est $ 2.39M, composée du salaire de 26.8% et des bonus 73.2%, y compris les actions et options de la société. détient directement 0.13% des actions de la société, d'une valeur de $ 423.23K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.4 ans et 3.7 ans.

Informations clés

Gilmore O’Neill

Directeur général

US$2.4m

Rémunération totale

Pourcentage du salaire du PDG	26.8%
Durée du mandat du directeur général	2.3yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	1.5yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Recent updates

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Dec 28

Analyse de la rémunération des PDG

Comment la rémunération de Gilmore O’Neill a-t-elle évolué par rapport aux bénéfices de Editas Medicine?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$193m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$2m	US$641k	-US$153m
Sep 30 2023	n/a	n/a	-US$195m
Jun 30 2023	n/a	n/a	-US$206m
Mar 31 2023	n/a	n/a	-US$219m
Dec 31 2022	US$9m	US$356k	-US$220m

Rémunération vs marché: La rémunération totale de Gilmore ($USD 2.39M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.46M ).

Rémunération et revenus: La rémunération de Gilmore a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Gilmore O’Neill (60 yo)

2.3yrs

Titularisation

US$2,392,309

Compensation

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Gilmore O’Neill	President	2.3yrs	US$2.39m	0.13% $ 377.4k
Erick Lucera	CFO & Executive VP	1.3yrs	US$2.69m	0.028% $ 80.4k
Linda Burkly	Executive VP & Chief Scientific Officer	1.2yrs	US$1.73m	0.018% $ 50.3k
Baisong Mei	Executive VP & Chief Medical Officer	2.2yrs	US$1.14m	0.052% $ 148.1k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	11.7yrs	pas de données	pas de données
George Church	Co-Founder & Scientific Advisory Board Member	11.7yrs	pas de données	pas de données
Gregory Whitehead	Executive VP and Chief Technical & Quality Officer	less than a year	pas de données	pas de données
Cristi Barnett	Corporate Communications & Investor Relations	no data	pas de données	pas de données
Charlene Stern	Executive VP & General Counsel	no data	pas de données	pas de données
Linea Aspesi	Executive VP & Chief People Officer	1.5yrs	pas de données	pas de données
Caren Deardorf	Executive VP and Chief Commercial & Strategy Officer	less than a year	pas de données	pas de données

1.5yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de EDIT n'est pas considérée comme expérimentée (ancienneté moyenne 1.4 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Gilmore O’Neill	President	no data	US$2.39m	0.13% $ 377.4k
Feng Zhang	Co-Founder & Scientific Advisory Board Member	no data	pas de données	pas de données
George Church	Co-Founder & Scientific Advisory Board Member	no data	pas de données	pas de données
Emma Reeve	Independent Chairman of the Board	3yrs	US$238.24k	0% $ 0
Andrew Hirsch	Independent Director	7.3yrs	US$210.56k	0.0024% $ 7.0k
Jessica Hopfield	Independent Director	6.6yrs	US$231.07k	0.082% $ 235.6k
Elliott Levy	Independent Director	1.4yrs	US$264.88k	0% $ 0
David Scadden	Independent Director	5.6yrs	US$213.06k	0% $ 0
Bernadette Connaughton	Independent Director	2.9yrs	US$215.06k	0% $ 0
Meeta Chatterjee	Independent Director	3.8yrs	US$205.56k	0% $ 0

3.8yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EDIT sont considérés comme expérimentés (ancienneté moyenne 3.7 ans).

Editas Medicine Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Recent updates

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Consensus revenue estimates fall by 13%

New major risk - Revenue and earnings growth

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Insider selling

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

First quarter 2024 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine Q2 2022 Earnings Preview

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease